Is mTOR inhibition a therapeutic option in chroniclymphocytic leukemia?

摘要

Targeting the mammalian target of rapamycin (mTOR) is a promising strategy for the treatment of solid and hematological malignancies. Rapamycin and related compounds (rapalogs), everolimus and temsirolimus, have demonstrated significant activity against a variety of cancers, including mantle cell lymphoma, renal cell cancer and neuroendocrine carcinoma [1-3]#